arbutus biopharma - ABUS
ABUS
Close Chg Chg %
3.27 0.23 7.03%
Closed Market
3.50
+0.23 (7.03%)
Volume: 1.44M
Last Updated:
Mar 28, 2025, 4:00 PM EDT
Company Overview: arbutus biopharma - ABUS
ABUS Key Data
| Open $3.27 | Day Range 3.26 - 3.54 |
| 52 Week Range 2.30 - 4.73 | Market Cap $619.64M |
| Shares Outstanding 189.49M | Public Float 147.08M |
| Beta 1.93 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.38 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 989.22K |
ABUS Performance
| 1 Week | 6.71% | ||
| 1 Month | 1.45% | ||
| 3 Months | 9.03% | ||
| 1 Year | 35.66% | ||
| 5 Years | 189.26% |
ABUS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About arbutus biopharma - ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
ABUS At a Glance
Arbutus Biopharma Corp.
701 Veterans Circle
Warminster, Pennsylvania 18974
| Phone | 1-267-469-0914 | Revenue | 18.14M | |
| Industry | Pharmaceuticals: Major | Net Income | -72,849,000.00 | |
| Sector | Health Technology | Employees | 44 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
ABUS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 22.871 |
| Price to Book Ratio | 4.006 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.884 |
| Enterprise Value to Sales | 16.406 |
| Total Debt to Enterprise Value | 0.029 |
ABUS Efficiency
| Revenue/Employee | 248,506.849 |
| Income Per Employee | -997,931.507 |
| Receivables Turnover | 7.635 |
| Total Asset Turnover | 0.107 |
ABUS Liquidity
| Current Ratio | 5.871 |
| Quick Ratio | 5.871 |
| Cash Ratio | 5.603 |
ABUS Profitability
| Gross Margin | 92.261 |
| Operating Margin | -430.153 |
| Pretax Margin | -401.571 |
| Net Margin | -401.571 |
| Return on Assets | -42.875 |
| Return on Equity | -59.99 |
| Return on Total Capital | -63.491 |
| Return on Invested Capital | -55.326 |
ABUS Capital Structure
| Total Debt to Total Equity | 8.226 |
| Total Debt to Total Capital | 7.601 |
| Total Debt to Total Assets | 6.039 |
| Long-Term Debt to Equity | 7.825 |
| Long-Term Debt to Total Capital | 7.23 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Arbutus Biopharma - ABUS
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 6.91M | 10.99M | 39.02M | 18.14M | |
Sales Growth
| +15.02% | +58.92% | +255.11% | -53.51% | |
Cost of Goods Sold (COGS) incl D&A
| - | 1.75M | 1.43M | 1.40M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.98M | 1.75M | 1.43M | 1.40M | |
Depreciation
| 1.98M | 1.75M | 1.43M | 1.40M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | -18.60% | -1.61% | - |
Gross Income
| - | 9.24M | 37.59M | 16.74M | |
Gross Income Growth
| - | - | +307.06% | -55.48% | - |
Gross Profit Margin
| - | +84.05% | +96.34% | +92.26% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 62.21M | 80.89M | 100.82M | 94.77M | |
Research & Development
| 47.48M | 65.50M | 84.41M | 73.70M | |
Other SG&A
| 14.72M | 15.38M | 16.41M | 21.07M | |
SGA Growth
| -17.42% | +30.03% | +24.64% | -6.00% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 537.00K | 1.87M | 2.23M | 69.00K | |
EBIT after Unusual Expense
| (57.81M) | (73.52M) | (65.46M) | (78.10M) | |
Non Operating Income/Expense
| 617.00K | 132.00K | 2.17M | 5.71M | |
Non-Operating Interest Income
| 741.00K | 127.00K | 2.19M | 5.69M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 4.01M | 2.86M | 1.73M | 459.00K | |
Interest Expense Growth
| +90.28% | -28.77% | -39.59% | -73.41% | |
Gross Interest Expense
| 4.01M | 2.86M | 1.73M | 459.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (61.20M) | (76.25M) | (65.01M) | (72.85M) | |
Pretax Income Growth
| +59.59% | -24.59% | +14.74% | -12.05% | |
Pretax Margin
| -885.16% | -693.91% | -166.62% | -401.57% | |
Income Tax
| - | - | - | 4.44M | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (63.75M) | (76.25M) | (69.46M) | (72.85M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (63.75M) | (76.25M) | (69.46M) | (72.85M) | |
Net Income Growth
| +58.53% | -19.61% | +8.91% | -4.89% | |
Net Margin Growth
| -921.97% | -693.91% | -178.01% | -401.57% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (63.75M) | (76.25M) | (69.46M) | (72.85M) | |
Preferred Dividends
| - | - | 12.12M | 12.14M | - |
Net Income Available to Common
| (75.87M) | (88.39M) | (69.46M) | (72.85M) | |
EPS (Basic)
| -1.0004 | -0.8319 | -0.4602 | -0.4389 | |
EPS (Basic) Growth
| +65.36% | +16.84% | +44.68% | +4.63% | |
Basic Shares Outstanding
| 75.84M | 106.24M | 150.94M | 165.96M | |
EPS (Diluted)
| -1.0004 | -0.8319 | -0.4602 | -0.4389 | |
EPS (Diluted) Growth
| +65.36% | +16.84% | +44.68% | +4.63% | |
Diluted Shares Outstanding
| 75.84M | 106.24M | 150.94M | 165.96M | |
EBITDA
| (55.29M) | (69.90M) | (61.80M) | (76.63M) | |
EBITDA Growth
| +20.23% | -26.42% | +11.59% | -24.00% | |
EBITDA Margin
| -799.70% | -636.12% | -158.37% | -422.41% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 5.20 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.103 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | -0.236 | |
| Last Quarter’s Earnings | -0.07 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.38 | Next Fiscal Year Estimate | -0.10 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 5 | 1 |
| Mean Estimate | -0.10 | -0.04 | -0.24 | -0.10 |
| High Estimates | -0.09 | -0.02 | -0.16 | -0.10 |
| Low Estimate | -0.13 | -0.06 | -0.32 | -0.10 |
| Coefficient of Variance | -18.47 | -45.54 | -30.94 | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Buy |
SEC Filings for Arbutus Biopharma - ABUS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Arbutus Biopharma - ABUS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Robert Alan Beardsley Director | 157,600 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Anuj Hasija Director | 157,600 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Lindsay Androski President and CEO; Director | 310,422 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Joseph Bishop | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Joseph Bishop | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Matthew Gline | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Matthew Gline | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Anuj Hasija | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Roivant Sciences Ltd. | 38,847,462 | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Lindsay Androski | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 11, 2025 | Robert Alan Beardsley | N/A | Opening Balance – Initial SEDI Report | 0.00 |
| Mar 3, 2025 | Roivant Sciences Ltd. | 38,847,462 | Conversion or exchange | 0.00 |
| Feb 21, 2025 | Karen Sims | 1,046,400 | Grant of options | 3,442,656.00 |
| Feb 21, 2025 | David C. Hastings | 2,104,300 | Grant of options | 6,923,147.00 |
| Feb 21, 2025 | David C. Hastings | 249,824 | Grant of rights | 0.00 |
| Feb 21, 2025 | John Christopher Naftzger | 138,067 | Grant of rights | 0.00 |
| Feb 21, 2025 | John Christopher Naftzger | 1,100,800 | Grant of options | 3,621,632.00 |
| Feb 21, 2025 | Michael J. McElhaugh | 1,658,003 | Grant of rights | 0.00 |
| Feb 21, 2025 | Michael J. McElhaugh | 2,494,218 | Grant of options | 8,205,977.22 |
| Feb 21, 2025 | Karen Sims | 155,494 | Grant of rights | 0.00 |